Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739908 · ClinicalTrials.gov registry record · Phase 2
A Study of CX157 (TriRima) for the Treatment of Depression
A Phase 2 study, sponsored by CeNeRx BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT00739908: Completed Phase 2 study, sponsored by CeNeRx BioPharma.
NCT00739908 is a Phase 2 study that has completed, run by CeNeRx BioPharma. The registered enrollment target is 285 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (114% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00739908, a Phase 2 study, has completed, sponsored by CeNeRx BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of CX157 in these subjects.
Primary Outcome
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item checklist designed to measure the overall severity of depressive symptoms in patients with MDD \[Montgomery, 1979\]. Items are rated on a scale of 0-6, with scores ranging from 0 to 60 with 0 being symptom free and 60 being the most severe depression. MADRS was assessed at randomization and Weeks 1, 2, 4 and 6 of the study.
Interventions
- DRUG Placebo
- DRUG CX157 (TriRima)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00739908 record still lists
NCT00739908 is an interventional study that assigns participants to a tested intervention. The registered 285 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (114% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00739908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00739908 about?
NCT00739908 is a clinical study titled "A Study of CX157 (TriRima) for the Treatment of Depression". The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of...
What is the current status of trial NCT00739908?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2008-09. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00739908?
The interventions under investigation include: Placebo (DRUG), CX157 (TriRima) (DRUG).
Who is sponsoring clinical trial NCT00739908?
This trial is sponsored by CeNeRx BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00739908's enrollment target sits among peer trials
285 192nd of 2000 higher than 1,806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03412877 · 285 participants · Phase 2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- NCT04537936 · 285 participants · NA
Psychotherapy Intervention for Latinos With Adv Cancer
- NCT04965675 · 285 participants · Phase 3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
- NCT05320835 · 285 participants · NA
A Setting Focus Overdose Prevention Intervention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia